NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-08-31
Reading CTEV? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Claritev aims to improve profit and cash flow. Operating income rose from a loss of $7.6 million to a gain of $6.6 million. Revenue stayed steady near $240 million per quarter. The company plans positive free cash flow up to $10 million in 2026.
The company still loses money and cash flow is unstable. Revenue growth is weak and may not improve. Earnings misses happened in recent quarters. The turnaround may stall or fail.
The market expects about 4% revenue growth. Our fair value is near $186, reflecting cautious optimism. We see risk in cash flow and profit stability.
Breaks if: Free cash flow remains negative for full FY26
Continue to improve operating income and generate positive cash flow through operational efficiency and execution.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CTEV represents a speculative growth investment. The company is currently loss-making but has shown strong revenue growth and improved cash flow, indicating potential for future profitability.
The market appears to price CTEV as justified, with a low fragility tier. Valuation is considered cheap compared to peers, but there is a notable expectations gap, suggesting that the market may not fully account for the company's recent performance.
Management is focused on driving revenue growth and improving operating income, with recent results showing strong performance in these areas. However, there is a near-term risk of missing earnings expectations, which has occurred in recent quarters.
The long-term thesis hinges on the performance of the broader healthcare sector and whether key competitors continue to deliver strong earnings. Additionally, any cuts to guidance from CTEV would be a significant negative signal.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Operating income increased from $6.6 million in 2026-Q1 to $23.4 million in 2026-Q2. Net cash from operating activities improved from negative $45.8 million in Q1 to positive $92.7 million in Q2. Management is delivering improved operating income and cash flow as committed.
“CFO: 'Operating income of $23.4 million in Q2 2026, net cash provided by operating activities of $92.7 million.'”
“CFO: 'Operating income of $6.6 million in Q1 2026, net cash used in operating activities of $45.8 million.'”
Breaks if: Operating income falls below $0 in any quarter next year
Continue to improve operating income and generate positive cash flow through operational efficiency and execution.
Stated as a priority in 2 of last 2 quarters. Operating income increased from $6.6 million in 2026-Q1 to $23.4 million in 2026-Q2. Net cash from operating activities improved from negative $45.8 million in Q1 to positive $92.7 million in Q2. Management is delivering improved operating income and cash flow as committed.
“CFO: 'Operating income of $23.4 million in Q2 2026, net cash provided by operating activities of $92.7 million.'”
“CFO: 'Operating income of $6.6 million in Q1 2026, net cash used in operating activities of $45.8 million.'”
Breaks if: Quarterly revenue falls below $230 million next year
Maintain and grow quarterly revenue near the $240 million level to support financial stability and growth.
Overall, CTEV's fundamentals are on track, but elevated risks and potential earnings misses warrant careful observation. Not investment advice.
